Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis
暂无分享,去创建一个
M. Maurer | A. Dispenzieri | G. Palladini | M. Gertz | G. Merlini | Y. Ando | G. Palladini | A. Wechalekar | V. Sanchorawala | R. Comenzo | M. Grogan | I. Lousada | M. Maurer | Y. Ando | M. Gertz